Dr. Hussain on Results of the PROfound Trial in mCRPC

Maha Hussain, MD, FACP, FASCO
Published: Thursday, Oct 10, 2019



Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the results of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Data presented at the 2019 ESMO Congress demonstrated that olaparib (Lynparza) improved radiographic progression-free survival (rPFS) versus physician's choice of abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in men with heavily pretreated mCRPC and homologous recombination repair (HRR) gene alterations.

In the trial, investigators reported a median rPFS of 7.39 months in patients with BRCA1/2 or ATM alterations (cohort A) treated with olaparib versus 3.55 months in those treated with hormone therapy (HR, 0.34; 95% CI, 0.25-0.47; P <.0001). Importantly, the time to pain progression was significantly delayed with olaparib versus hormone therapy, says Hussain. A trend toward improved overall survival was also noted in the olaparib arm, but further follow-up is needed to make a definitive assessment, she concludes.
SELECTED
LANGUAGE


Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the results of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Data presented at the 2019 ESMO Congress demonstrated that olaparib (Lynparza) improved radiographic progression-free survival (rPFS) versus physician's choice of abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in men with heavily pretreated mCRPC and homologous recombination repair (HRR) gene alterations.

In the trial, investigators reported a median rPFS of 7.39 months in patients with BRCA1/2 or ATM alterations (cohort A) treated with olaparib versus 3.55 months in those treated with hormone therapy (HR, 0.34; 95% CI, 0.25-0.47; P <.0001). Importantly, the time to pain progression was significantly delayed with olaparib versus hormone therapy, says Hussain. A trend toward improved overall survival was also noted in the olaparib arm, but further follow-up is needed to make a definitive assessment, she concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x